Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.68
TEAR's Cash to Debt is ranked lower than
66% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. TEAR: 0.68 )
Ranked among companies with meaningful Cash to Debt only.
TEAR' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: No Debt Max: No Debt
Current: 0.68
Equity to Asset -0.06
TEAR's Equity to Asset is ranked lower than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TEAR: -0.06 )
Ranked among companies with meaningful Equity to Asset only.
TEAR' s Equity to Asset Range Over the Past 10 Years
Min: -1.1  Med: 0.69 Max: 0.96
Current: -0.06
-1.1
0.96
F-Score: 4
Z-Score: -24.63
M-Score: -4.20
WACC vs ROIC
13.75%
-290.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -75.41
TEAR's Operating margin (%) is ranked lower than
71% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. TEAR: -75.41 )
Ranked among companies with meaningful Operating margin (%) only.
TEAR' s Operating margin (%) Range Over the Past 10 Years
Min: -48893.1  Med: -393.81 Max: -75.41
Current: -75.41
-48893.1
-75.41
Net-margin (%) -88.52
TEAR's Net-margin (%) is ranked lower than
72% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. TEAR: -88.52 )
Ranked among companies with meaningful Net-margin (%) only.
TEAR' s Net-margin (%) Range Over the Past 10 Years
Min: -75902.17  Med: -451.21 Max: -88.52
Current: -88.52
-75902.17
-88.52
ROA (%) -88.76
TEAR's ROA (%) is ranked lower than
84% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. TEAR: -88.76 )
Ranked among companies with meaningful ROA (%) only.
TEAR' s ROA (%) Range Over the Past 10 Years
Min: -132.11  Med: -75.14 Max: -37.9
Current: -88.76
-132.11
-37.9
ROC (Joel Greenblatt) (%) -346.73
TEAR's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. TEAR: -346.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEAR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7452.46  Med: -3437.26 Max: -346.73
Current: -346.73
-7452.46
-346.73
Revenue Growth (3Y)(%) 68.80
TEAR's Revenue Growth (3Y)(%) is ranked higher than
96% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. TEAR: 68.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEAR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 11.25 Max: 69.6
Current: 68.8
0
69.6
EBITDA Growth (3Y)(%) 25.50
TEAR's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TEAR: 25.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEAR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.7  Med: 4.25 Max: 97.5
Current: 25.5
-77.7
97.5
EPS Growth (3Y)(%) 9.20
TEAR's EPS Growth (3Y)(%) is ranked higher than
68% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. TEAR: 9.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEAR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -78.6  Med: 11.6 Max: 71.5
Current: 9.2
-78.6
71.5
» TEAR's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

TEAR Guru Trades in Q4 2015

Chuck Royce 85,000 sh (-15.00%)
» More
Q1 2016

TEAR Guru Trades in Q1 2016

Chuck Royce 85,000 sh (unchged)
» More
Q2 2016

TEAR Guru Trades in Q2 2016

Chuck Royce 85,000 sh (unchged)
» More
Q3 2016

TEAR Guru Trades in Q3 2016

Jim Simons 19,800 sh (New)
Chuck Royce 85,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:EDTXF, OTCPK:PRFMF, NAS:CGIX, OTCPK:ILIU, NAS:CHEK, NAS:OPGN, OTCPK:GNWSF, OTCPK:MHTX, OTCBB:INIS, NAS:DRIO, NAS:CAPN, NAS:GENE, NAS:BIOC, OTCPK:VRTT, NAS:HTGM, OTCPK:AVDX, NAS:APPY, NAS:ROSG, OTCPK:MNLIF, NAS:ROKA » details
Traded in other countries:TLB.Canada, OCV1.Germany,
TearLab Corp is an in-vitro diagnostic company. The Company commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.

TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.

Ratios

vs
industry
vs
history
P/S 0.67
TEAR's P/S is ranked higher than
89% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TEAR: 0.67 )
Ranked among companies with meaningful P/S only.
TEAR' s P/S Range Over the Past 10 Years
Min: 0.67  Med: 19.86 Max: 505.05
Current: 0.67
0.67
505.05
Current Ratio 4.65
TEAR's Current Ratio is ranked higher than
76% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TEAR: 4.65 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s Current Ratio Range Over the Past 10 Years
Min: 0.19  Med: 2.26 Max: 20.62
Current: 4.65
0.19
20.62
Quick Ratio 3.99
TEAR's Quick Ratio is ranked higher than
75% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TEAR: 3.99 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.84 Max: 19.15
Current: 3.99
0.14
19.15
Days Inventory 107.52
TEAR's Days Inventory is ranked lower than
56% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. TEAR: 107.52 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s Days Inventory Range Over the Past 10 Years
Min: 61.57  Med: 162.26 Max: 383.57
Current: 107.52
61.57
383.57
Days Sales Outstanding 31.73
TEAR's Days Sales Outstanding is ranked higher than
90% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. TEAR: 31.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.73  Med: 72.25 Max: 1487.77
Current: 31.73
31.73
1487.77
Days Payable 54.58
TEAR's Days Payable is ranked lower than
52% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. TEAR: 54.58 )
Ranked among companies with meaningful Days Payable only.
TEAR' s Days Payable Range Over the Past 10 Years
Min: 28.27  Med: 115.69 Max: 705.37
Current: 54.58
28.27
705.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.50
TEAR's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. TEAR: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEAR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -133.7  Med: -56.1 Max: -5.5
Current: -5.5
-133.7
-5.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.03
TEAR's Price/Median PS Value is ranked higher than
97% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TEAR: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
TEAR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.98 Max: 19.82
Current: 0.03
0.03
19.82
Earnings Yield (Greenblatt) (%) -58.70
TEAR's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TEAR: -58.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEAR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -122.61  Med: 0 Max: 0
Current: -58.7
-122.61
0

More Statistics

Revenue (TTM) (Mil) $27.69
EPS (TTM) $ -0.65
Beta2.32
Short Percentage of Float2.07%
52-Week Range $0.47 - 1.75
Shares Outstanding (Mil)53.60

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 38 44
EPS ($) -0.63 -0.28
EPS w/o NRI ($) -0.63 -0.28
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ETFs with exposure to TearLab Corp. : December 9, 2016 Dec 09 2016
TEARLAB CORP Financials Nov 17 2016
TearLab Granted Extension by Nasdaq Nov 16 2016
TearLab Granted Extension by Nasdaq Nov 16 2016
TearLab to Present at the 7th Annual Craig-Hallum Alpha Select Conference Nov 14 2016
TEARLAB CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Nov 14 2016
ETF’s with exposure to TearLab Corp. : November 10, 2016 Nov 10 2016
TEARLAB CORP Files SEC form 10-Q, Quarterly Report Nov 09 2016
TearLab Corp. :TEAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016 Nov 08 2016
TearLab reports 3Q loss Nov 07 2016
TearLab reports 3Q loss Nov 07 2016
TearLab Corporation Reports Third Quarter and September Year-To-Date 2016 Financial Results Nov 07 2016
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 07 2016
TearLab Corporation Reports Third Quarter and September Year-To-Date 2016 Financial Results Nov 07 2016
Q3 2016 TearLab Corp Earnings Release - Before Market Open Nov 07 2016
TearLab Corporation to Release Third Quarter 2016 Financial Results Oct 20 2016
TearLab Corporation to Release Third Quarter 2016 Financial Results Oct 20 2016
TearLab's Co-Promotion With PRN A Positive, But Rodman & Renshaw Isn't Raising Its Estimates Oct 14 2016
TearLab and PRN Physician Recommended Nutriceuticals Announce Co-Promotion Agreement Oct 13 2016
TEARLAB CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Oct 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)